Premium
EGCG promotes cell growth inhibition and reprograms mesenchymal‐epithelial transition by restoring CCN5/WISP2 in triple negative breast cancer cells in vitro and in vivo
Author(s) -
Ghosh Arnab,
Das Amlan,
Banerjee Snigdha,
Baltezor Michael,
Zeng Liang,
Banerjee Sushanta K.
Publication year - 2018
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.2018.32.1_supplement.668.10
Subject(s) - matricellular protein , cancer research , epithelial–mesenchymal transition , triple negative breast cancer , cancer cell , biology , reprogramming , mesenchymal stem cell , cell growth , stromal cell , growth inhibition , carcinogenesis , microbiology and biotechnology , cancer , breast cancer , cell , extracellular matrix , metastasis , biochemistry , genetics
Background and Objective CCN5/WISP‐2, a matricellular secretory protein that is localized in both cytoplasm and nucleus, is mainly expressed in luminal cells rather than basal cell types in breast cancer tumors. Endogenous CCN5 plays critical role in promoting growth arrest and reprograming Mesenchymal to Epithelial Transition(MET), inhibition of migration and invasion, overall inducing the invasive to non‐invasive phenotypes. Thus, we hypothesize that targeting endogenous CCN5 restoration in Triple‐negative‐breast cancer (TNBC) cells could be an ideal strategy to prevent the progression of TNBC. To test the hypothesis, we set out to identify a molecule that has the capability to restore CCN5 in TNBC cells. Here we report that CCN5, which is normally absent in TNBC cells can be restored by a common dietary supplement epigallocatechin‐3‐gallate (EGCG), an ester of epigallocatechin and gallic acid, and is a type of catechin, to promote growth arrest and reverse EMT. Methods Effect of EGCG on breast cancer cells were characterized by in vitro protein and gene expression profilings, cytotoxic assays, colony formation assays, migration assays, anchorage independent growth assays. In vivo effect of EGCG on tumorigenesis was investigated in xenograft model of immunosuppressive mice. Result and Conclusion EGCG treatment in breast cancer cells significantly elevated and restored CCN5 expression in TNBC cells along with inhibition of cell proliferation, migration and colony formation and induction of apoptosis. Reprogramming of mesenchymal to epithelial transition(MET) was also observed in EGCG‐treated TNBC cells. Oral administration of EGCG resulted in drastic inhibition of tumor growth and propagation in immunosuppressive mouse xenografts of MDA‐MB‐231 cells, along with restoration of CCN5 expression. Altogether, these studies clearly indicate that EGCG is an ideal molecule to restore CCN5 in TNBC cells in preventing the TNBC growth, progression and possibly make these cells susceptible to anti‐estrogen treatment, as restoration of CCN5 causes estrogen receptor(ER)‐α in TNBC cells. Moreover, it is reasonable to speculate that the CCN5 pathways probably play an important part in the anti‐tumorigenic role of EGCG in TNBC cells. Support or Funding Information Supported by Midwest Biomedical Research Foundation and VA Merit Grant. This abstract is from the Experimental Biology 2018 Meeting. There is no full text article associated with this abstract published in The FASEB Journal .